| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 20, 2019Genoa, Italy
- Eight posters including one oral presentation support ongoing research and clinical experience with Hizentra®, the first and only subcutaneous immunoglobulin (Ig) therapy approved to address...
-
May 16, 2019Recipients from the US and Netherlands will be recognized in Marburg, Germany on Friday, 24 May
16 May 2019 Marburg, Germany - 16 May 2019 - Global biotherapeutics leader CSL Behring today announced that the company has named five recipients of the 2019 Professor Heimburger Award for...
-
May 15, 2019Dr. McKenzie will be accountable for leading CSL’s global end-to-end supply chain organization and its accompanying strategy.
15 May 2019 KING OF PRUSSIA, PA – May 15, 2019 - CSL today named Dr. Paul McKenzie, an accomplished global leader with diverse biotechnology experience, as Chief Operating Officer (COO),...
-
Apr 25, 2019New vial options deliver on CSL Behring’s heritage of innovation by providing more alternatives to patients
25 Apr 2019 KING OF PRUSSIA, Pa. – 25 April 2019 – Global biotherapeutics leader CSL Behring today announced that the US Food and Drug Administration (FDA) has approved 4- and 5-gram vial...
-
Apr 9, 2019Leading global biotech company brings innovative therapies for life-threatening medical conditions to UAE
Dubai, UAE - 9 April, 2019 – CSL Behring, a global biotherapeutics leader, has inaugurated its regional headquarters at Dubai Science Park (DSP), a holistic science-focused business community...
-
Mar 26, 2019CSL Behring announced today that Japan’s Ministry of Health, Labour and Welfare has approved two of its immunoglobulin therapies for the treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): Hizentra® and Privigen®
26 Mar 2019 Hizentra® [human normal immunoglobulin, 20%, subcutaneous] is the first and only subcutaneous immunoglobulin approved for the maintenance treatment of CIDP in Japan, based on findings...
-
Feb 4, 2019Reinforces Commitment to Providing Global Bleeding Disorders Community with Access to Care and Efforts to Increase Awareness
04 Feb 2019 MONTREAL and KING OF PRUSSIA, Pa. – 4 February 2019 – The World Federation of Hemophilia (WFH) and global biotherapeutics leader CSL Behring today announced that the company has...
-
Jan 16, 2019Forbes Recognizes the Global Biotechnology Leader in its Top 50 Best Employers for Diversity 2019
16 Jan 2019 KING OF PRUSSIA, Pa. – January 16, 2019 – Forbes magazine has named global biotechnology leader CSL Limited as one of The Best Employers for Diversity in the United States. CSL,...
-
Jan 7, 2019CSL announced that it will present at the 2019 J.P. Morgan Annual Healthcare Conference.
07 Jan 2019 King of Prussia, Pa – Global biotechnology giant CSL Limited, parent company of biotherapeutics leader CSL Behring and world-leading influenza provider Seqirus, today announced that...
-
Dec 6, 2018Perreault leads the fifth largest biotechnology company in the world with more than 22,000 employees providing lifesaving medicines to patients in more than 60 countries.
06 Dec 2018 KING OF PRUSSIA, Pa. – December 6, 2018 – Paul Perreault, CEO and Managing Director of CSL Limited, is one of the Philadelphia Business Journal’s Most Admired CEOs for 2018,...